Clinical Trial: First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06984094) titled 'First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults' on May 14.

Brief Summary: This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: RSV Infections

Intervention: BIOLOGICAL: SCB-1019T

SCB-1019T (bivalent recombinant RSV vaccine candidate) consists of two recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)) and RSV B strain (SCB-1019T(B)).

BIOLOGICAL: SCB-1022

SCB-1022 (combination recombinant RS...